86 results about "Equol" patented technology

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

The present invention provides an equol-producing lactic acid bacteria-containing composition comprising, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol. Such a composition is effective for the prevention and alleviation of malaise inclusive of climacteric disturbance in middle-aged and elderly women for which no effective prophylactic method or alleviating means has heretofore been available.

Disclosed is an improved method for preparing the isoflavonoid compound (+ / −)-equol, the method comprising reducing an organic diester of the isoflavone daidzein under hydrogen-transfer conditions using palladium hydroxide catalyst.

A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.

A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

The invention belongs to the technical field of microorganism and discloses a clostridium bifermentans for generating equol by degrading daidzein and bacteria agent and application thereof. The clostridium bifermentans for generating equol by degrading daidzein zx-7 is collected in the China General Microbiological Culture Collection Center, and the collection number is CGMCC NO.1995. The clostridium bifermentans CGMCC NO.1995 can degrade daidzein to generate equol, the low density lipoprotein content of rat serum is remarkably reduced, the ratio of the high-density lipoprotein to the low-density lipoprotein is obviously increased, the elimination of cholesterol in rat is facilitated, and the host health is favored. The clostridium bifermentans can be used for preparing animal feed, a preparation for eliminating cholesterol and a fermented product of soy or bean pulp.

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

The isoflavone equol has the ability to mimic estrogen at the receptor level, as well as the ability to mitigate the deleterious effects of dihydrotestosterone (DHT) in vivo, thus resulting in potential health benefits for both men and women. Only an approximated one-third of the global population has the inherent ability to produce equol. Diet and colonic bacterial composition play a large role in natural equol production. The present invention can increase the probability of producing significant quantities of equol in vivo. Experimentation has shown the repeatable and measurable evidence of equol. Data from male test subjects indicates clinically significant positive effects on androgenic alopecia and acne vulgaris.

The invention discloses an AUH-JLC159, whose preservation number is CGMCC No. 5304, and the usage thereof in preparation of (-)-5-OH-equol. The invention comprises the following steps: (1) cultivating the bacterial strain AUH-JLC159; (2) carrying out co-culture of genistein and bacterial strain AUH-JLC159 and separation and purification of the metabolite: switching the seed liquid of bacterial strain AUH-JLC159 to the BHI medium, and cultivating for 2-3 days in an anaerobic working station, thereby the substrate genistein is transformed into (-)-5-OH-equol. Purifying and separating the metabolite. The AUH-JLC159 provided by the invention can transform the substrate genistein to 5-OH-EQ with high efficiency under the anaerobic condition; thereby solving the problem of microbe biosynthesis and resource scarcity of 5-OH-EQ, and has a great promotion effects for physiology and pharmacological activities of 5-OH-EQ and new drug research and development.

The present invention discloses a Proteus mirabilis strain and a method for producing S-equol through daidzein conversion by using the Proteus mirabilis strain, wherein the strain is preserved in the China Center for Type Culture Collection on November 13, 2011, and a preservation number is CCTCC M 2011390. In the prior art, the existing technology is difficult to prepare the S-equol through conversion. With the present invention, the problem in the prior art is solved, and a single function microorganism strain for directly converting a prochiral compound daidzein into a chiral compound S-equol and a preparation method thereof are provided; and compared with the strictly anaerobic equol conversion strains and the mixing bacteria conversion in the previous reports, the Proteus mirabilis LH-52 strain of the present invention is a facultative anaerobe, and is more suitable for industrial production.

The invention discloses a molecular impriting solid-phase extraction small column capable of high-selectively purifying and enriching diethyl stiboestrol (DES) from sample solution for determining residual amount of artificially-synthetic estrin diethyl stiboestrol (DES) in animal food and its preparation method. Said invention uses diethyl stiboestrol as molecular template to prepare molecular imprinting polymer, it is a cross-linked polymer with fixed hole size and form and definite arranged function group, and has the 'memory' function for steresotructure of diethyl stiboestrol template molecule, so that said material can be fileld into polypropylene small column so as to can obtain the diethyl stiboestrol molecular imprinting solid-phase extraction small column. As compared with general solvent extraction method and C18 solid-phase extraction method said invented imprinting column is more simple, quick and higher in efficiency.

The invention relates to a preparation method of (S)-equol, which aims to solve the problem of complex operation in the existing preparation method of (S)-equol. The preparation method comprises the following steps: by using daidzein as the main material, carrying out hydroxy protection, catalytic hydrogenation, dehydration and chiral catalytic reduction to prepare the (S)-equol. The invention has the advantages of cheap and accessible raw materials and low cost, is simple to operate, and is suitable for industrial scale-up production; and the yield is 60-70%. The invention is applicable to the field of synthesis of medicine compounds.

The invention discloses Enterococcus faecium BY1, a method for producing equol by using the Enterococcus faecium and application of the Enterococcus faecium, and belongs to the field of biochemical industry. The bacteria were collected in China General Microbiological Culture Collection Center on March 28, 2011, and the collection number is CGMCC NO.4707. The Enterococcus faecium has the capacity of transforming a daidzin part in isoflavone into the equol, and can be used for preparing food containing the equol.

A phytoestrogen blend was developed using a pharmaceutical platform technology to identify the time course of active components and effect time course of these components in the biophase after administration of a red clover extract. This phytoestrogen blend consists of biochanin A, daidzein, equol and genistein. The recommended daily dosage ranges from 5 to 200 mg of total isoflavone.

Disclosed herein are processes for the preparation of isoflavonoids, in particular haginin E, equol, daidzein, formononetin and the like, in which 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran is used as a common starting material.

An oral composition for increasing equol production by inner-intestinal bacteria, wherein such composition contains difructose anhydride as an active ingredient to activate the equol production function of inner-intestinal bacteria.

An object of the present invention is to provide a method for measuring equol in a biological sample by an immunological method, a kit for the measurement, and a method for determining equol-producing ability of a subject.The measurement method of the present invention is characterized in that S-equol is used as at least one antigen selected from the group consisting of a standard antigen used for the preparation of a standard curve and a labeled antigen that competes with equol in a biological sample. The kit of the present invention is characterized in including S-equol as at least one antigen selected from the group consisting of the standard antigen and the labeled antigen. The determination method of the present invention includes steps of measuring equol in a biological sample derived from a subject who has ingested soybean isoflavone by an immunological method using S-equol as at least one antigen selected from the group consisting of the standard antigen and the labeled antigen, and determining an equol-producing ability of the subject based on the measured value of equol obtained in the above step.

The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same.The present invention makes it possible to efficiently obtain useful components containing equol from the fermented soybean hypocotyl by subjecting an equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution as an extractant. The present invention reduces the content of saponin, which causes an unpleasant taste, by sequentially subjecting the equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution and ethanol, while efficiently extracting equol and glycitein.

Subject of the invention is a method for the production of isoflavanes from isoflavones, whereby in a first reaction step (a) the 4-keto group of the isoflavone is reduced in a enantioselective manner, whilst the 2,3-double bond is maintained, to the 4-hydroxy compound.

An anhydrous crystalline form of S-equol has been discovered. Form I, the anhydrous crystalline form of S-equol has been isolated and characterized for the first time. As compared to other forms of S-equol, such as the known hydrate or other solvate forms, the anhydrous crystalline form of S-equol has improved properties.

A phytoestrogen blend was developed using a pharmaceutical platform technology to identify the time course of active components and effect time course of these components in the biophase after administration of a red clover extract. This phytoestrogen blend consists of biochanin A, daidzein, equol and genistein. The recommended daily dosage ranges from 5 to 200 mg of total isoflavone.

The invention provides a synthetic method for equol. The synthetic method comprises the following steps: with daidzein as a raw material, subjecting daidzein to an esterification reaction to obtain a compound B; subjecting the compound B to olefinic-bond conjugation and a reduction reaction of a carbonyl group so as to obtain a compound C; subjecting the compound C to a dehydration reaction so as to obtain a compound D; and carrying out double-bond hydrogenation on the compound D so as to obtain equol. The synthetic method provided by the invention has the advantages of short synthesis steps, simple operation, economic performance, environmental protection, yield of 70% or above in each step, obviously increased overall yield and suitability for industrial mass production.

An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc.The equol-containing fermented soybean hypocotyl material of the invention is obtained by fermenting soybean hypocotyls using at least one microorganism having an equol-producing ability by utilizing at least one daidzein compound selected from the group consisting of diadzein glycosides, daidzein, and dihydrodaidzein.

An object of the present invention is to provide a whitening agent containing a novel whitening substance as an effective ingredient. The above object is attained by providing a whitening agent containing equol and / or equol glycoside, in which one or more glycosyl groups bind to the hydroxyl group(s) of equol, as an effective ingredient.